CLINICAL DEVELOPMENT OF TWO REPLICATION-DEFECTIVE CHIMPANZEE ADENOVIRUS (ADC) VECTORS, TERMED ADC6 AND ADC7

两种复制缺陷型黑猩猩腺病毒 (ADC) 载体（称为 ADC6 和 ADC7）的临床开发

• 批准号: 9542514
• 负责人: HILDEGUND ERTL
• 金额: $ 15.34万
• 依托单位: WISTAR INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-08-01 至 2018-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9542514
• 关键词: Adenovirus Vector; Adenoviruses; Advanced Development; Animal Model; Clinical Trials; DNA Vaccines; Data; Development; Development Plans; Formulation; Future; HIV; HIV vaccine; Human; Licensure; Pan Genus; Pharmaceutical Preparations; Phase; Poxviridae; Preparation; Production; Proteins; Recombinants; Update; adeno-associated viral vector; cGMP production; clinical development; interest; nonhuman primate; pre-clinical; product development; programs; success; vaccine candidate; vector

The intent of this activity is to provide support to multifunctional teams for advanced development and manufacture of HIV vaccine candidates that have demonstrated success in non-human primate (NHP) challenge studies, equivalent preclinical animal models or early human clinical trials, and have demonstrated manufacturing feasibility. The supported activities will allow the further development of the current leading HIV vaccine platforms. Platforms of interest include, recombinant HIV proteins, POX viruses, DNA vaccines, replication detective adenovirus vectors, and adeno-associated virus vectors.

这项活动的目的是为多功能团队提供支持，以先进开发和生产 HIV 候选疫苗，这些候选疫苗已在非人类灵长类动物 (NHP) 挑战研究、等效临床前动物模型或早期人类临床试验中取得成功，并已证明生产可行性。 所支持的活动将使当前领先的艾滋病毒疫苗平台得到进一步开发。感兴趣的平台包括重组 HIV 蛋白、痘病毒、DNA 疫苗、复制检测腺病毒载体和腺相关病毒载体。